Please login to the form below

Not currently logged in
Email:
Password:

sHPT

This page shows the latest sHPT news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

sHPT parathyroidism is a serious condition that affects a high proportion of CKD patients receiving dialysis. ... It is estimated that only around 25% of eligible patients take cinacalcet, mainly because most people with sHPT have a substantial number of

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... The first new treatment to be approved for sHPT in more

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    Like its predecessor, the new calcimimetic drug - called Parsabiv ( etelcalcetide) - has been developed for the treatment of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD) who are on dialysis. ... Clinical trials also

  • Pharma deals for April 2012 Pharma deals for April 2012

    The acquisition of Kai Pharma for $315m will give Amgen access to Kai's lead product KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease ... 357. KAI Pharmaceuticals / Amgen (a). Acquisition.

  • Amgen to buy Kai Pharmaceuticals for $315m

    SHPT is when too much parathyroid hormone is produced by the parathyroid glands in the neck due to low levels of calcium in the blood. ... According to Amgen, there are about 1.64m people with CKD who have SHPT in developed countries where data is

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • PAN and DJM win prestigious Global Award

    Mimpara is approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and it was for this indication that the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics